Product Code: 596200688
Market barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand one of them?
We researched 8 renal cell carcinoma (RCC) treatments to see what happens to their share of the European market when oncologists can't prescribe freely. The result: 5 of those brands saw a net loss.
But 3 of them made significant net gains. Is your brand one of them?
You'll learn how market barriers affect share for 8 major treatments from Bayer/Amgen, Novartis, Pfizer, and Roche.
Plus you'll see which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.
Get Answers to Key Questions about RCC Drug Brands
- Afinitor (everolimus; Novartis): Afinitor takes market share from only two brands. Which two?
- Avastin (bevacizumab; Roche): Which brand takes more than twice as much share from Avastin as any other?
- Inlyta (axitinib; Pfizer): Would eliminating market barriers help Inlyta catch up to Afinitor?
- Nexavar (sorafenib; Bayer/Amgen): Are doctors who don't prescribe either brand more likely to consider Nexavar or Inlyta?
- Proleukin (aldesleukin; Novartis): Which two barriers do more doctors experience with Proleukin than any other brand?
- Sutent (sunitinib; Pfizer): Which barrier is responsible for nearly a quarter of Sutent's impressive share gain?
- Torisel (temsirolimus; Pfizer): Only one market barrier earns Torisel a net share gain. Which one?
- Votrient (pazopanib; Novartis): Votrient and Afinitor are just about equally prescribed. Which brand has the edge in market share?
- Barriers cost most brands market share: Five of the eight surveyed brands saw a net share loss due to barriers. Only three saw net gains.
- Eliminating barriers would tighten up the market: Especially the top of the market, where it would make a big dent in the #1 brand's lead.
- Most brands are heavily prescribed: A majority of doctors prescribe nearly all of the brands surveyed. The most prescribed brand has almost a 10% lead over its nearest rival.
- Clear market share winner: of the three brands that gain share due to market barriers, one gains more than twice as much as the closest competitor.
- Barrier effect varies widely: The number of doctors who experience each market barrier varies widely from brand to brand.
- Reimbursement and guidelines have the greatest impact: barriers related to reimbursement, patient type restrictions, and guidelines affect more prescriptions than any others.
- Brand awareness is high: With one exception, no more than 1% of doctors surveyed were unaware of any given brand.
- Overall market access is good: In Europe, market barriers affect less than 20% of prescription decisions.
Exploring Market Access Issues
Market Access Impact: RCC explores key issues affecting RCC drug manufacturers. You'll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest effect?
How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 150 medical oncologists-30 from each EU5 country (France, Italy, Germany, Spain, UK)-chosen from the largest community of validated physicians in the world.
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with melanoma in total in the last month
We conducted the survey between April 4th and 11th, 2016.